Taysha Gene Therapies, Inc. (TSHA) Return on equity 2022–2025
Taysha Gene Therapies, Inc. (TSHA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-44.1%FY2025 · since FY2022: -17493.6% → -44.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -44.1% | +80.7 pp |
| FY2024 | -124.8% | +24.0 pp |
| FY2023 | -148.9% | +17344.7 pp |
| FY2022 | -17493.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Net marginTSHA Gross profitTSHA Gross marginTSHA Operating incomeTSHA Operating marginTSHA Operating cash flowTSHA Free cash flowTSHA Capital expendituresTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Total liabilitiesTSHA Shareholders’ equityTSHA overview →